Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Accelerate Diagnostics, IncAXDX · Entity 78156 | Director | June 28, 2024 | July 01, 2024 |
| BIODESIX INCBDSX · Entity 6053 | Director | January 02, 2026 | January 06, 2026 |
| GenMark Diagnostics, Inc.GNMK · Entity 140086 | Director · President and CEO | January 23, 2020 | January 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Accelerate Diagnostics, Inc
Report date June 28, 2024 · Filed July 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,891 |
Reported balance
After 2024-06-28 transaction · row 1
1 source rowRow 1 · 2024-06-28 · Exercise / conversion · Acquired 4,737 · Balance 36,891 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 18,947 |
Reported balance
After 2024-06-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-28 · Exercise / conversion · Disposed 4,737 · Balance 18,947 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F2: On June 28, 2023, the reporting person was granted a total of 23,684 RSUs, which vest in five equal annual installments beginning on June 28, 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Massarany Family Trust dated November 15, 2012 | 3,000 |
Reported balance
Holding disclosure · report date 2024-06-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.
F2: On June 28, 2023, the reporting person was granted a total of 23,684 RSUs, which vest in five equal annual installments beginning on June 28, 2024.
BIODESIX INC
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,484 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 7,484 · Balance 7,484 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2036-01-01 | Direct | 6,354 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 6,354 · Balance 6,354 F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").
F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.
GenMark Diagnostics, Inc.
Report date January 23, 2020 · Filed January 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 822,174 |
Ending reported balance
After 2020-01-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-01-23 · Exercise / conversion · Acquired 75,049 · Balance 851,094 Row 2 · 2020-01-23 · Sale · Disposed 28,920 · Balance 822,174 F1: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted market stock units. F2: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $4.80 to $5.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. |
| Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 47,371 |
Reported balance
After 2020-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-23 · Exercise / conversion · Acquired 22,407 · Balance 47,371 F4: The MSUs vest in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. |
| Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 164,858 |
Reported balance
After 2020-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-23 · Exercise / conversion · Acquired 52,642 · Balance 164,858 F5: The MSUs vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. |
| Common StockSEC Table I · non-derivative | IndirectMassarany Family Trust dated November 15, 2012 | 524,568 |
Reported balance
Holding disclosure · report date 2020-01-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 524,568 F3: Mr. Massarany is the trustee of the Massarany Family Trust and may be deemed to have beneficial ownership of these securities, to the extent of any indirect pecuniary interest in his distributive shares therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted market stock units.
F2: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $4.80 to $5.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price.
F3: Mr. Massarany is the trustee of the Massarany Family Trust and may be deemed to have beneficial ownership of these securities, to the extent of any indirect pecuniary interest in his distributive shares therein.
F4: The MSUs vest in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index.
F5: The MSUs vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2019 Filed Feb 21, 2019 19:07 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 5,562 | $6.16 | $34,261.92 |
DisclosureSEC source: 0001487371-19-000042 · wf-form4_155079390848313.xml · nonDerivative · entry 2 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904,000 F2 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| February 18, 2019 Filed Feb 21, 2019 19:07 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantMarket Stock Units · Derivative | 217,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001487371-19-000042 · wf-form4_155079390848313.xml · derivative · entry 4 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,500 Underlying: Common Stock · 217,500 shares Expires not disclosed F4 · shares: Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. F5 · derivative.exercise_date: The MSUs vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F5 · derivative.expiration_date: The MSUs vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F4 · derivative.underlying_shares: Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. Read SEC document |
| February 18, 2019 Filed Feb 21, 2019 19:07 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 217,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-19-000042 · wf-form4_155079390848313.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 909,562 F1 · kind: The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2010 Equity Incentive Plan. The restricted stock units vest 25% on February 18, 2020 and the remaining shares subject to such award vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 18:25 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 15,166 | $5.90 | $89,479.40 |
DisclosureSEC source: 0001487371-19-000024 · wf-form4_154845869892952.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 692,062 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted market stock units. Read SEC document |
| January 17, 2019 Filed Jan 22, 2019 19:37 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Exercise / conversionMarket Stock Units · Derivative | 40,229 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001487371-19-000016 · wf-form4_154820382398269.xml · derivative · entry 3 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,771 Underlying: Common Stock · 40,229 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. F3 · derivative.exercise_date: The MSUs vest in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F3 · derivative.expiration_date: The MSUs vest in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F2 · balance_after: Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. Read SEC document |
| January 17, 2019 Filed Jan 22, 2019 19:37 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Exercise / conversionCommon Stock | 40,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-19-000016 · wf-form4_154820382398269.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 707,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:32 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 5,884 | $5.08 | $29,890.72 |
DisclosureSEC source: 0001487371-18-000237 · wf-form4_154352713703901.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,999 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| November 20, 2018 Filed Nov 26, 2018 16:50 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 8,047 | $4.84 | $38,947.48 |
DisclosureSEC source: 0001487371-18-000222 · wf-form4_154326900136009.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,883 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| November 05, 2018 Filed Nov 6, 2018 16:53 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,561 | $4.85 | $7,570.85 |
DisclosureSEC source: 0001487371-18-000212 · wf-form4_154154122333328.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 680,930 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| August 24, 2018 Filed Aug 27, 2018 13:10 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 6,203 | $7.16 | $44,413.48 |
DisclosureSEC source: 0001487371-18-000175 · wf-form4_153538981216118.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 682,491 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| August 21, 2018 Filed Aug 22, 2018 17:37 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 6,010 | $7.39 | $44,413.90 |
DisclosureSEC source: 0001487371-18-000161 · wf-form4_153497383826102.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 688,694 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 19:25 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,004 | $7.20 | $7,228.80 |
DisclosureSEC source: 0001134554-18-000005 · wf-form4_153359792297990.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 694,704 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. F2 · balance_after: The amount reported includes 1,500 shares of the Issuer's common stock acquired under the GenMark Diagnostics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan since the reporting person last filed a Form 4 with the Securities Exchange Commission. Read SEC document |
| May 23, 2018 Filed May 24, 2018 18:47 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 4,168 | $6.88 | $28,675.84 |
DisclosureSEC source: 0001487371-18-000113 · wf-form4_152720198741158.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 694,208 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| May 21, 2018 Filed May 22, 2018 16:56 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 5,459 | $6.91 | $37,721.69 |
DisclosureSEC source: 0001487371-18-000108 · wf-form4_152702254975642.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,376 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| May 02, 2018 Filed May 4, 2018 16:42 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,055 | $6.18 | $6,519.90 |
DisclosureSEC source: 0001487371-18-000088 · wf-form4_152546651633023.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,835 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| February 27, 2018 Filed Feb 27, 2018 19:43 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantMarket Stock Units · Derivative | 110,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001487371-18-000054 · wf-form4_151977857378963.xml · derivative · entry 4 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires not disclosed F4 · shares: Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. F5 · derivative.exercise_date: The MSUs vest in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F5 · derivative.expiration_date: The MSUs vest in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F4 · derivative.underlying_shares: Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 19:43 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 17,300 | $4.17 | $72,141.00 |
DisclosureSEC source: 0001487371-18-000054 · wf-form4_151977857378963.xml · nonDerivative · entry 2 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 704,890 F2 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 19:43 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 365,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-18-000054 · wf-form4_151977857378963.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,190 F1 · kind: The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2010 Equity Incentive Plan. Of the amount reported, 35,000 restricted stock units vest in full (100%) on February 23, 2019. The remaining restricted stock units vest 25% on February 23, 2019 and in 12 equal quarterly installments thereafter. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 18:42 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 6,584 | $4.37 | $28,772.08 |
DisclosureSEC source: 0001487371-18-000031 · wf-form4_151925656255256.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,190 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| February 02, 2018 Filed Feb 6, 2018 20:25 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,252 | $5.13 | $6,422.76 |
DisclosureSEC source: 0001487371-18-000021 · wf-form4_151796670318845.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,774 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. F2 · balance_after: The amount reported includes 2,069 shares of the Issuer's common stock acquired under the GenMark Diagnostics, Inc. 2013 Employee Stock Purchase Plan since the reporting person last filed a Form 4 with the Securities Exchange Commission. Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 18:04 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 8,252 | $4.74 | $39,114.48 |
DisclosureSEC source: 0001487371-17-000243 · wf-form4_151130547466796.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,957 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| November 02, 2017 Filed Nov 3, 2017 19:49 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,588 | $7.24 | $11,497.12 |
DisclosureSEC source: 0001487371-17-000224 · wf-form4_150975293964820.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,209 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 14:37 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 8,311 | $9.45 | $78,538.95 |
DisclosureSEC source: 0001487371-17-000183 · wf-form4_150351341272987.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,797 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 13:26 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,629 | $10.33 | $16,827.57 |
DisclosureSEC source: 0001487371-17-000168 · wf-form4_150186758352031.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,108 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. F2 · balance_after: The reporting person transferred 1,374 shares of the Issuer's common stock into the Massarany Family Trust dated November 15, 2012 in connection with the applicable restricted stock units vesting event. Read SEC document |
| May 19, 2017 Filed May 23, 2017 16:51 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 8,239 | $12.89 | $106,200.71 |
DisclosureSEC source: 0001487371-17-000113 · wf-form4_149557269089925.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,111 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. F2 · balance_after: The reporting person transferred 7,400 shares of the Issuer's common stock into the Massarany Family Trust dated November 15, 2012 in connection with the applicable restricted stock units vesting event. Read SEC document |
| May 02, 2017 Filed May 4, 2017 17:10 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,571 | $13.34 | $20,957.14 |
DisclosureSEC source: 0001487371-17-000099 · wf-form4_149393222369127.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,750 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. F2 · balance_after: The reporting person transferred 1,432 shares of the Issuer's common stock into the Massarany Family Trust dated November 15, 2012 in connection with the applicable restricted stock units vesting event. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 19:54 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,653 | $12.18 | $20,133.54 |
DisclosureSEC source: 0001487371-17-000077 · wf-form4_148910724626696.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,753 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. F2 · balance_after: The reporting person transferred 1,472 shares of the Issuer's common stock into the Massarany Family Trust dated November 15, 2012 in connection with the applicable restricted stock units vesting event. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:20 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantMarket Stock Units · Derivative | 63,684 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001487371-17-000052 · wf-form4_148798199606161.xml · derivative · entry 3 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,684 Underlying: Common Stock · 63,684 shares Expires not disclosed F3 · shares: Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. F4 · derivative.exercise_date: The MSUs vest in three equal installments, on each of December 31, 2017, December 31, 2018, and December 31, 2019; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F4 · derivative.expiration_date: The MSUs vest in three equal installments, on each of December 31, 2017, December 31, 2018, and December 31, 2019; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F3 · derivative.underlying_shares: Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:20 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 191,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-17-000052 · wf-form4_148798199606161.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,878 F1 · shares: The amount reported reflects restricted stock units granted to the reporting person pursuant to the Issuer's 2010 Equity Incentive Plan. The restricted stock units vest 25% on February 22, 2018 and the remaining shares subject to such award vest in 12 equal quarterly installments thereafter. Read SEC document |
| February 21, 2017 Filed Feb 21, 2017 20:02 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 33,537 | $10.08 | $338,052.96 |
DisclosureSEC source: 0001487371-17-000037 · wf-form4_148772530920339.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,824 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. F2 · balance_after: The reporting person transferred 29,020 shares of the Issuer's common stock into the Massarany Family Trust dated November 15, 2012 in connection with the applicable restricted stock units vesting event. Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 17:46 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,142 | $11.58 | $13,224.36 |
DisclosureSEC source: 0001487371-17-000023 · wf-form4_148616197567997.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,381 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. F2 · balance_after: The reporting person transferred 1,861 shares of the Issuer's common stock into the Massarany Family Trust dated November 15, 2012 in connection with the applicable restricted stock units vesting event. Read SEC document |
| January 19, 2017 Filed Jan 20, 2017 18:48 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Exercise / conversionMarket Stock Units · Derivative | 26,649 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001487371-17-000012 · wf-form4_148495612345493.xml · derivative · entry 6 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,299 Underlying: Common Stock · 26,649 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Each MSU represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. F7 · derivative.exercise_date: The MSUs vest in three equal installments, on each of December 31, 2016, December 31, 2017, and December 31, 2018; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F7 · derivative.expiration_date: The MSUs vest in three equal installments, on each of December 31, 2016, December 31, 2017, and December 31, 2018; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F5 · derivative.underlying_shares: Each MSU represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. Read SEC document |
| January 19, 2017 Filed Jan 20, 2017 18:48 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Exercise / conversionMarket Stock Units · Derivative | 18,116 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001487371-17-000012 · wf-form4_148495612345493.xml · derivative · entry 5 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,468 Underlying: Common Stock · 18,116 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Each MSU represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. F6 · derivative.exercise_date: The MSUs vest in three equal installments, on each of December 31, 2015, December 31, 2016, and December 31, 2017; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F6 · derivative.expiration_date: The MSUs vest in three equal installments, on each of December 31, 2015, December 31, 2016, and December 31, 2017; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F5 · derivative.underlying_shares: Each MSU represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. Read SEC document |
| January 19, 2017 Filed Jan 20, 2017 18:48 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 27,124 | $12.47 | $338,236.28 |
DisclosureSEC source: 0001487371-17-000012 · wf-form4_148495612345493.xml · nonDerivative · entry 3 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,384 F2 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted MSUs. F3 · balance_after: The reporting person transferred 42,859 shares of the Issuer's common stock into the Massarany Family Trust dated November 15, 2012 in connection with the applicable MSU vesting event. Read SEC document |
| January 19, 2017 Filed Jan 20, 2017 18:48 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Exercise / conversionCommon Stock | 51,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-17-000012 · wf-form4_148495612345493.xml · nonDerivative · entry 2 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Based on actual achievement for the one-year performance period, the recipient was issued 194.6% of the market stock units ("MSUs") which vested as of December 31, 2016. Read SEC document |
| January 19, 2017 Filed Jan 20, 2017 18:48 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Exercise / conversionCommon Stock | 18,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-17-000012 · wf-form4_148495612345493.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 18:00 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,196 | $11.08 | $13,251.68 |
DisclosureSEC source: 0001487371-16-000401 · wf-form4_148132441172924.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,384 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. F2 · balance_after: The reporting person transferred 1,929 shares of the Issuer's common stock into the Massarany Family Trust dated November 15, 2012 in connection with the applicable restricted stock units vesting event. Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 17:36 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,148 | $10.30 | $11,824.40 |
DisclosureSEC source: 0001487371-16-000373 · wf-form4_147829540555991.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,509 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. F2 · balance_after: The reporting person transferred 1,855 shares of the Issuer's common stock into the Massarany Family Trust dated November 15, 2012 in connection with the applicable restricted stock units vesting event. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 18:35 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,186 | $8.69 | $10,306.34 |
DisclosureSEC source: 0001487371-16-000355 · wf-form4_147346053794152.xml · nonDerivative · entry 1 MASSARANY HANY · CIK 0001134554 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,512 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. F2 · balance_after: The reporting person transferred 1,939 shares of the Issuer's common stock into the Massarany Family Trust dated November 15, 2012 in connection with the applicable restricted stock units vesting event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.